You are here

Case Report

Aripiprazole (Abilify) and Tardive Dyskinesia

Thomas Schwartz, MD, and Shafi Raza, MD
PDF version: 
Second-generation atypical antipsychotic drugs carry a lower risk of extra­pyramidal symptoms and tardive dyskinesia compared with conventional agents, but they are not without their dangers. The case report of a 46-year-old patient demonstrates the point that the newer agents should be used according to their FDA-approved indications, when possible, and that patients using aripiprazole, an “atypical atypical” agent, need to be carefully monitored.